ARCHIVES

Rev/Vel/Dex Response Rate High In Phase I/II Study

This article is from The Cancer Letter archive.

Vol. 31 No. 1 | January 25, 2008

Download PDF Visit The Full Archive

Related Articles

NCI SBIR Offers $10 million in 10 Awards

February 18, 2011

In Brief: Duke’s Gary Lyman to Co-Direct Fred Hutch Outcomes Research

January 10, 2014

Letter to the Editors: Loss Of ET2 Would Be Disheartening, Member Of Study Section Says

February 20, 1998

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

May 28, 2004

FDA Simplifies Reporting Of Adverse Events

June 18, 1993

SWOG Wins Funding For H. Pylori Trial.

November 21, 2008